Transforming Molecular Diagnostics

Rapid Detection of Infectious Diseases

Rapid and comprehensive detection of pathogens is an important strategy in reducing the spread of infectious disease. Our EasyScreen™ Detection Kits identify a larger number of pathogen targets in a shorter time frame than conventional methods.

Efficient Workflow

Traditional techniques for identifying viral, bacterial and protozoan pathogens require a high degree of knowledge and can take days to get a result. Our EasyScreen™ Detection Kits replace these methodologies with a single efficient workflow that requires less training, staff and hands-on-time, and gives a result in under 5 hours.


The Genetic Signatures GS1 platform is a high-throughput bench top platform that performs both nucleic acid extraction and automated 384-well PCR set-up for the entire EasyScreen™ range. Our EasyScreen™ Detection Kits are also compatible with most existing automated nucleic acid extraction and real-time PCR instruments.

Standardised Sample Processing

Our EasyScreen™ Sample Processing Kits offer streamlined preparation of nucleic acids direct from the primary specimen. Our sample processing method is common for all specimen types leading to workflow efficiencies and standardised results between laboratories.

3Base™ Multiplex Technology

Our 3Base™ technology forms the basis of the EasyScreen™ Detection Kits. 3Base™ allows for simpler design of molecular assays facilitating the simultaneous detection of multiple targets. 3base™ is compatible with both RNA and DNA targets.

Product Pipeline

Genetic Signatures has a number of new detection kits in development. All new products follow a defined development and commercialisation process comprised of (i) Experimental Analytical Validation, and (ii) Clinical and Regulatory Validation prior to release.

Clinical Validation of Genetic Signatures EasyScreen™ Sexual Health Detection Kit Commenced

| ASX Announcements, Latest News | No Comments

Key step in progress toward clinical validation, regulatory approval, and market release of the EasyScreen™ Sexually Transmitted Infection (STI) Detection Kit Next step in Genetic Signatures product range expansion Large addressable…

EasyScreen™ Kit shows superior specificity detecting Dientamoeba fragilis in animal faeces

| Latest News | No Comments

A recent publication in Veterinary Parasitology by Chan et al. “Detection of Dientamoeba fragilis in animal faeces using species-specific real-time PCR assay” has shown that the EasyScreen™ Enteric Protozoan Detection Kit shows…

Genetic Signatures issues first tranche of $14 million share placement

| ASX Announcements, Latest News | No Comments

Molecular diagnostics company Genetic Signatures Limited (ASX:GSS or the Company) is pleased to announce that further to its ASX Announcement of 2nd September 2016, the Board on Thursday 8 September…

Genetic Signatures Limited Completes $14m Capital Raising

| ASX Announcements, Latest News | No Comments

Molecular diagnostics company Genetic Signatures Ltd (ASX: GSS) is pleased to announce that it has successfully completed an institutional placement to raise $14 million through the issue of 29.8 million…